GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
WEB2 days ago · GSK on Wednesday unveiled promising topline Phase III data for a combo regimen of its RSV vaccine Arexvy and shingles shot Shingrix, touting a comparable immunogenicity profile to the individual vaccines.
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB3 days ago · AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50...
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB2 days ago · GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in...
ACIP Evidence to Recommendations for Use of GSK Adjuvanted …
WEBSep 5, 2024 · On May 3, 2023, the Food and Drug Administration (FDA) approved GSK RSVPreF3 vaccine (AREXVY) for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged ≥60 years. 9 RSVPreF3 is a 1-dose (0.5 mL) subunit vaccine containing stabilized RSV prefusion F protein in combination with adjuvant ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
Federal Officials Revise Recommendations for R.S.V. Vaccine
WEBJun 26, 2024 · The Food and Drug Administration has approved three R.S.V. vaccines. Two of them, GSK’s Arexvy and Pfizer’s Abrysvo, were approved in May last year and were administered during the fall and...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine…
WEBAug 17, 2023 · AREXVY was approved by the US Food and Drug Administration (FDA) on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older. It was the world’s first vaccine for RSV for older adults, a common, contagious virus that can lead to serious respiratory illness. 7
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
WEB1 day ago · Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) and Shingrix (zoster vaccine recombinant, adjuvanted).
- Some results have been removed
Skip to content